ASCO CMO Dr. Richard L. Schilsky Recognized as Society for Clinical Trials Fellow

May 19, 2017

The Society for Clinical Trials (SCT) has recognized ASCO Senior Vice President and Chief Medical Officer (CMO) Richard L. Schilsky, MD, FACP, FASCO, with the distinction of Fellow of the Society for Clinical Trials (FSCT). SCT created this fellowship in 2005 to honor its Society members who have made significant advancements to clinical trials. Dr. Schilsky was awarded this honor at the 2017 SCT Annual Meeting, May 7-10, 2017.

A distinguished leader in the oncology field, Dr. Schilsky specializes in new drug development and gastrointestinal cancers. His impressive and dedicated career in oncology includes serving as chair of the Cancer and Leukemia Group B, a national cooperative clinical research group funded by the National Cancer Institute (NCI). Dr. Schilsky has also served as both the chief of hematology/oncology in the Department of Medicine at the University of Chicago and as director of the University of Chicago Comprehensive Cancer Center, and is currently working with the clinical research training programs developed by ASCO as ASCO’s first CMO. In these roles, Dr. Schilsky has overseen the development and conduct of countless cancer clinical trials, many of which have led to important changes in oncology practice and/or approval of new indications for cancer drugs.

 “Having served the oncology community and ASCO for years, Dr. Schilsky’s leadership in and passion for clinical research continue to inspire oncology professionals everywhere,” said ASCO CEO Clifford A. Hudis, MD, FACP, FASCO. “We are proud to celebrate Dr. Schilsky’s well-deserved recognition as an SCT Fellow.”

Before becoming ASCO CMO, Dr. Schilsky served in leadership positions for a variety of ASCO committees, including chair of the Cancer Research Committee, the Gastrointestinal Cancers Symposium Program Committee, and the Government Relations Committee. He also served as ASCO president from 2008 to 2009. Under his current leadership as CMO, ASCO has launched its first prospective clinical trial, the Targeted Agent and Profiling Utilization Registry (TAPUR) study, and the Center for Research and Analytics (CENTRA), ASCO’s hub for all its research activities.

Back to Top